Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Jan 31, 2023
Open Peer Review Period: Jan 30, 2023 - Mar 27, 2023
Date Accepted: Mar 28, 2023
Date Submitted to PubMed: Mar 29, 2023
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

Dong Z, Zhou J, Xu Z, Ni Z, He Y, Lin H, Jiang G, Sun X, Zhang L, Chen X

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

JMIR Res Protoc 2023;12:e46101

DOI: 10.2196/46101

PMID: 36990111

PMCID: 10337463

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Per the author's request this version is not available.